| 10.27 0.46 (4.69%) | 05-22 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.59 | 1-year : | 17.05 |
| Resists | First : | 12.5 | Second : | 14.59 |
| Pivot price | 9.26 |
|||
| Supports | First : | 8.64 | Second : | 6.26 |
| MAs | MA(5) : | 9.85 |
MA(20) : | 9.11  |
| MA(100) : | 9.79 |
MA(250) : | 6.57 |
|
| MACD | MACD : | 0 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 72.1 |
D(3) : | 68.6 |
| RSI | RSI(14): 56.7 |
|||
| 52-week | High : | 13.69 | Low : | 2.3 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ COEP ] has closed below upper band by 14.6%. Bollinger Bands are 30.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 10.06 - 10.1 | 10.1 - 10.15 |
| Low: | 9.67 - 9.72 | 9.72 - 9.77 |
| Close: | 9.73 - 9.81 | 9.81 - 9.89 |
Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.
Sun, 18 May 2025
(COEP) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Thu, 01 May 2025
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Fri, 25 Apr 2025
Coeptis Therapeutics Subsidiary to Merge With Dogecoin Mining Company - marketscreener.com
Fri, 25 Apr 2025
Coeptis Therapeutics and Z Squared to Merge - citybiz
Fri, 25 Apr 2025
Massive Crypto Pivot: Biotech Firm Acquires 9,000 Dogecoin Miners in Industry-Shaking Merger - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
PNK
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 3 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 19 (%) |
| Held by Institutions | 3.8 (%) |
| Shares Short | 63 (K) |
| Shares Short P.Month | 53 (K) |
| EPS | -5.1 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.5 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -93.3 % |
| Return on Equity (ttm) | -464.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.7 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -2.02 |
| PEG Ratio | 0 |
| Price to Book value | 6.85 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|